Topiramate (Qudexy XR) vs Topiramate (Topamax)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase · full Epilepsy pipeline
Topiramate (Qudexy XR)
Marketed by Upsher-Smith Laboratories, LLC
NCT01142193 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial of 249 participants. The primary clinical endpoint—percent reduction in weekly partial-onset seizure frequency over 11 weeks—was met, with a statistically significant advantage for USL255 over placebo (p<0.001).
Reported efficacy
Percent Reduction From Baseline in Weekly (7 Day) Partial-onset Seizure Frequency During the Titration Plus Maintenance Phase Compared to Baseline. (11 weeks): Percent Reduction From Baseline in Weekly (7 Day) Partial-onset Seizure Frequency During the Titration Plus Maintenance Phase Compared to Baseline. (11 weeks): USL255 39.5 Percent Reduction (range -227.3 to 100) | Placebo 21.65 Percent Reduction (range -531.2 to 100) (met)
Result source: NCT01142193
Topiramate (Topamax)
Marketed by Johnson & Johnson
NCT00266591 · Phase 3 · completed
The study was randomized and double-blind with 51 participants, and its primary endpoint was the clinical measure of time to withdrawal for therapeutic failure. However, the comparator arm is not identifiable in the available record and no primary-outcome results were posted, so the trial provides limited interpretable evidence.
Reported efficacy
Video-recorded EEG was primary efficacy measure. Baseline vEEG and the vEEG at Visit 4 (Days 19 to 20; end point DB treatment phase or early withdrawal) will be read by a blinded central reader: Primary endpoint, median % reduction from baseline in daily partial-onset-seizure rate (video-EEG): topiramate 25 mg/kg 20.4% vs placebo 13.1% (p=0.97); 15 mg/kg dose p=0.97 vs placebo; 5 mg/kg dose p=0.91 vs placebo -- no dose significantly better than placebo. (missed)
Result source: NCT00113815
Results for Epilepsy
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Topiramate (Qudexy XR) | Topiramate (Topamax) |
|---|---|---|
| Seizure frequency, % change | —Not posted · NCT00236717 | —Not posted · NCT00266591 |
| 50% responder rate | 33.9% vs 17.6%+16.3 vs placeboNCT01142193 | —Not posted · NCT00266591 |
| Seizure freedom | —Not posted · NCT00236717 | —Not posted · NCT00266591 |
Seizure frequency, % change
- Topiramate (Qudexy XR)
- —Not posted · NCT00236717
- Topiramate (Topamax)
- —Not posted · NCT00266591
50% responder rate
- Topiramate (Qudexy XR)
- 33.9% vs 17.6%+16.3 vs placeboNCT01142193
- Topiramate (Topamax)
- —Not posted · NCT00266591
Seizure freedom
- Topiramate (Qudexy XR)
- —Not posted · NCT00236717
- Topiramate (Topamax)
- —Not posted · NCT00266591
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Topiramate (Qudexy XR): 4 of 4 rows · Topiramate (Topamax): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Topiramate (Qudexy XR) | Topiramate (Topamax) |
|---|---|---|
| Dropout rate | 16.9% NCT01142193 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 | 34.3%Topiramate Monotherapya NCT01627860 · Phase 4 · registry result, not featured evidence · monotherapy show 5 more results30%Topiramate add-on Therapy NCT01627860 · Phase 4 · registry result, not featured evidence · combination 15.8% NCT01689649 · Phase 4 · registry result, not featured evidence — NCT00855738 · Phase 4 · registry result, not featured evidence 18.8%Group A BIA 2-093 + Topamax NCT02283814 · Phase 1 · registry result, not featured evidence · combination 12.5%Group B BIA 2-093 + Topamax NCT02283814 · Phase 1 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 9.7% NCT01142193 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 | 25.7%Topiramate Monotherapya NCT01627860 · Phase 4 · registry result, not featured evidence · monotherapy show 5 more results20%Topiramate add-on Therapy NCT01627860 · Phase 4 · registry result, not featured evidence · combination — NCT01689649 · Phase 4 · registry result, not featured evidence — NCT00855738 · Phase 4 · registry result, not featured evidence —Group A BIA 2-093 + Topamax NCT02283814 · Phase 1 · registry result, not featured evidence · combination —Group B BIA 2-093 + Topamax NCT02283814 · Phase 1 · registry result, not featured evidence · combination |
| Serious AEs | 1.6% NCT01142193 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 | 2.9%Topiramate Monotherapya NCT01627860 · Phase 4 · registry result, not featured evidence · monotherapy show 5 more results5%Topiramate add-on Therapy NCT01627860 · Phase 4 · registry result, not featured evidence · combination 0% NCT01689649 · Phase 4 · registry result, not featured evidence 0% NCT00855738 · Phase 4 · registry result, not featured evidence 0%Group A BIA 2-093 + Topamax NCT02283814 · Phase 1 · registry result, not featured evidence · combination 0%Group B BIA 2-093 + Topamax NCT02283814 · Phase 1 · registry result, not featured evidence · combination |
| Most frequent reported AEs | somnolence 12.1% (placebo 2.4%) dizziness 7.3% (placebo 5.6%) paraesthesia 6.5% (placebo 2.4%) NCT01142193 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 | a dizziness 28.6% hypoaesthesia 22.9% headache 17.1% NCT01627860 · Phase 4 · registry result, not featured evidence · monotherapy show 5 more resultsdizziness 20% headache 15% hyperhidrosis 10% NCT01627860 · Phase 4 · registry result, not featured evidence · combination weight loss 22.7% anorexia 12.1% fever 7.6% NCT01689649 · Phase 4 · registry result, not featured evidence somnolence 7.5% weight increased 5% dizziness 2.5% NCT00855738 · Phase 4 · registry result, not featured evidence somnolence 87.5% paraesthesia oral 50% headache 43.8% NCT02283814 · Phase 1 · registry result, not featured evidence · combination somnolence 81.3% abdominal distension 43.8% fatigue 37.5% NCT02283814 · Phase 1 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Topiramate (Qudexy XR)
show 1 more result
Topiramate (Topamax)
show 1 more result
show 1 more result
show 2 more results
show 2 more results
show 2 more results
Migraine
Shared mechanism: Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase · full Migraine pipeline
Topiramate (Qudexy XR)
Marketed by Upsher-Smith Laboratories, LLC
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Topiramate (Topamax)
Marketed by Johnson & Johnson
NCT00236509 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled, parallel-group trial in which 487 patients were randomized (480 planned) to three topiramate doses or placebo for 26 weeks. The primary endpoint, change in migraine frequency, is a clinical outcome; the 100 and 200 mg/day doses reduced it significantly versus placebo (p<0.001), but the 50 mg/day dose did not separate from placebo, so the primary comparison was only partly met and the grade is moderate. Figures are from the FDA label, which reports this study as Study 11.
Next expected readout: December 2027 · NCT05582837 (registry estimate)
Reported efficacy
Changes in length of time between the onset and cessation of painful migraine symptoms (migraine period) from the baseline. Safety evaluations conducted throughout the study.: Primary endpoint, change in mean 4-week migraine frequency (baseline to double-blind phase, ITT n=469): -1.3, -2.1 and -2.2 with topiramate 50, 100 and 200 mg/day vs -0.8 with placebo; 100 and 200 mg/day vs placebo p<0.001 (TOPAMAX label, Study 11 = TOPMAT-MIGR-001). (met)
Result source: NCT00236509
Results for Migraine
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Topiramate (Qudexy XR): no structured comparison results are available for Migraine.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Topiramate (Qudexy XR)'s landscape · Topiramate (Topamax)'s landscape